arrow
M

Maurício Lacerda Nogueira

faculdade de medicina de sao jose do rio preto
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using a two-dose primary protocol in children and adolescents (Immunita-002, Brazil): a phase IV one-year follow-up

灭活SARS-CoV-2疫苗(CoronaVac)采用两剂次基础免疫方案在儿童和青少年中的免疫原性和安全性(Immunita-002,巴西):一项为期一年的IV期随访研究

2026-11-110
OAAI
Genomic Surveillance Uncovers the Silent Spread of Avian Influenza Virus (H5N1 2.3.4.4b) Among Wild Birds and Mammals Along Brazil’s Southern Coast

基因组监测揭示巴西南部海岸野生鸟类和哺乳动物中H5N1 2.3.4.4b亚型禽流感病毒的隐秘传播

Viruses
IF3.5
2026-07-050
OA
PHENOTYPIC CHARACTERIZATION OF HISTORICAL AND CONTEMPORARY OROPOUCHE VIRUS STRAINS REVEALS DIVERGENT REPLICATION DYNAMICS IN MULTIPLE CELL LINES

历史和当代奥罗普切病毒株的表型特征分析揭示其在多种细胞系中具有不同的复制动力学

2026-04-250
OAAI
Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine

单剂量四价布他丹登革热疫苗的长期疗效和安全性

2026-03-040
PRE
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil

巴西流行地区12个月、双盲、随机、安慰剂对照的III期试验中,一种减毒活疫苗的登革热病毒疫苗在青少年中的安全性和免疫原性的最终结果

2025-12-080
PRE
Vector surveillance during a major chikungunya outbreak in northwestern São Paulo state, Brazil

在巴西圣保罗州西北部大规模奇卡ungi病毒疫情中的媒介监测

2025-11-141
PRE
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial

灭活全病毒SARS-CoV-2疫苗(CoronaVac)在巴西医疗保健专业人员中的有效性和安全性:PROFISCOV试验

Vaccine
IF3.5
2025-07-310
PRE
Lysergol exerts potent antiviral activity against the emerging Oropouche virus in vitro

麦角硫醇在体外对新兴的Oropouche病毒表现出强大的抗病毒活性。

2025-06-010
PRE
Identification of a putative new virus from the Jingmenvirus group in ticks from wild animals in Brazil

从巴西野生动物蜱中鉴定出一种可能的Jingmenvirus群新病毒

2025-01-011
OAAI
Spatiotemporal Dynamics of SARS-CoV-2 Variants During the First Year of the Pandemic Highlight the Earlier Emergence of the Zeta Variant of Interest in Brazil

大流行第一年SARS-CoV-2变体的时空动态突显了巴西感兴趣的Zeta变体的较早出现

2024-12-060
OAAI
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Butantan-DV在2-59岁参与者中的疗效和安全性: 来自巴西的双盲,随机,安慰剂对照,3期,多中心试验的结果

2024-11-012
PRE